PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30295336-6	2019	In addition, cisplatin experiments with cell counting kit-8, colony formation, and a xenograft mice model of NPC demonstrated that NEK2 contributed to proliferation and cisplatin resistance in vitro and in vivo.	Cisplatin	13-22	NIMA (never in mitosis gene a)-related expressed kinase 2	Mus musculus	131-135	
30295336-6	2019	In addition, cisplatin experiments with cell counting kit-8, colony formation, and a xenograft mice model of NPC demonstrated that NEK2 contributed to proliferation and cisplatin resistance in vitro and in vivo.	Cisplatin	169-178	NIMA (never in mitosis gene a)-related expressed kinase 2	Mus musculus	131-135	
30295336-7	2019	On the contrary, downregulation of NEK2 by short hairpin RNA inhibited NPC cell growth and increased the sensitivity of cisplatin treatment in vitro.	Cisplatin	120-129	NIMA (never in mitosis gene a)-related expressed kinase 2	Mus musculus	35-39	
30295336-9	2019	Targeting NEK2 has the potential to eradicate the cisplatin-based chemotherapy resistant NPC cells.	Cisplatin	50-59	NIMA (never in mitosis gene a)-related expressed kinase 2	Mus musculus	10-14	
20345485-9	2010	Furthermore, the combined administration of both Nek2 siRNA and CDDP suppressed tumor growth compared to either the single administration of Nek2 siRNA or the combined administration of control siRNA and CDDP.	Cisplatin	204-208	NIMA (never in mitosis gene a)-related expressed kinase 2	Mus musculus	49-53